Tech Company Financing Transactions

Syntimmune Funding Round

On 6/22/2017, Syntimmune received $50 million in Series B funding from Apple Tree Partners and private investors.

Transaction Overview

Company Name
Announced On
Transaction Type
Venture Equity
Series B

Apple Tree Partners (Lead Investor) (Sam Hall)

Proceeds Purpose
Funds from the Series B financing will further advance Syntimmune's clinical development program, which includes two ongoing Phase 1b/2a clinical trials of the company's lead drug candidate, SYNT001, in pemphigus and warm autoimmune hemolytic anemia.

Company Information

Company Status
Acquired or Merged
Mailing Address
116 Huntington Ave. 301
Boston, MA 02116
Email Address
Founded in 2013, Syntimmune is the world's leader in the biology of the neonatal Fc receptor (FcRn). Helmed by the most recognized experts in its field, Syntimmune is positioned to rapidly advance breakthrough therapies which co-opt this unique target.
Syntimmune LinkedIn Company Profile
Social Media
Syntimmune Company Twitter Account
Company News
Syntimmune News
Syntimmune on Facebook
Syntimmune on YouTube

Management Team

Email & Social
Chief Executive Officer
Jean Kress
  Jean Kress LinkedIn Profile  Jean Kress Twitter Account  Jean Kress News  Jean Kress on Facebook
Chief Financial Officer
John McBride
  John McBride LinkedIn Profile  John McBride Twitter Account  John McBride News  John McBride on Facebook
Chief Medical Officer
Mario Saltarelli
  Mario Saltarelli LinkedIn Profile  Mario Saltarelli Twitter Account  Mario Saltarelli News  Mario Saltarelli on Facebook
Vice President
Stephanie Haller
  Stephanie Haller LinkedIn Profile  Stephanie Haller Twitter Account  Stephanie Haller News  Stephanie Haller on Facebook
Vice President
Nicole Luosey
  Nicole Luosey LinkedIn Profile  Nicole Luosey Twitter Account  Nicole Luosey News  Nicole Luosey on Facebook
VP - Operations
Adam Hansard
  Adam Hansard LinkedIn Profile  Adam Hansard Twitter Account  Adam Hansard News  Adam Hansard on Facebook
VP - Regulatory Affairs
Donald Johns
  Donald Johns LinkedIn Profile  Donald Johns Twitter Account  Donald Johns News  Donald Johns on Facebook
VP - Regulatory Affairs
Leslie Stolz
  Leslie Stolz LinkedIn Profile  Leslie Stolz Twitter Account  Leslie Stolz News  Leslie Stolz on Facebook



Browse more venture capital transactions:

Prev: 6/22/2017: Celtra venture capital transaction
Next: 6/22/2017: GreatHorn venture capital transaction


Share this article


Where The Data Comes From

Our team works diligently to document every notable VC transaction. VC investment data records reported here are derived from company press releases and news coverage. The information comes to us via our partnership with, an affiliated venture.


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities


Business Glossary